Xiaoqiang Ding
Fudan University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Xiaoqiang Ding as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:52 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06884267 · Hyperkalemia Quality Improvement Program (HK-QIP) StudyAstraZeneca · active not recruiting · Hyperkalemia · principal investigator
- Ph4NCT06725810 · Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney DiseaseShanghai Zhongshan Hospital · recruiting · Chronic Kidney Disease Associated Anemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:52 UTC. The ranking covers the 200 most relevant of 313 PubMed records, and a shared surname and initials can bring in a namesake. All 313 on PubMed
- 1,719 citationsRCR 75.1
- Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med · 20141,435 citationsRCR 51.2
- Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.N Engl J Med · 2013590 citationsRCR 19.4
- 340 citationsRCR 17.9
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.Proc Natl Acad Sci U S A · 2019332 citationsRCR 11.4
- 237 citationsRCR 30.7
- A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models.Nat Biotechnol · 2025232 citationsRCR 61.1
- Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.Hepatology · 2015165 citationsRCR 5.9
- GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.Lancet Haematol · 2023146 citationsRCR 11.6
- Predictors of outcome after anterior temporal lobectomy: positron emission tomography.Neurology · 1994132 citationsRCR 5.6